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Protein ubiquitylation is involved in a plethora of cellular processes. While antibodies directed
at ubiquitin remnants (K-ɛ-GG) have improved the ability to monitor ubiquitylation using
mass spectrometry, methods for highly multiplexed measurement of ubiquitylation in tissues
and primary cells using sub-milligram amounts of sample remains a challenge. Here, we
present a highly sensitive, rapid and multiplexed protocol termed UbiFast for quantifying
~10,000 ubiquitylation sites from as little as 500 μg peptide per sample from cells or tissue in
a TMT10plex in ca. 5 h. High-field Asymmetric Waveform Ion Mobility Spectrometry
(FAIMS) is used to improve quantitative accuracy for posttranslational modification analysis.
We use the approach to rediscover substrates of the E3 ligase targeting drug lenalidomide
and to identify proteins modulated by ubiquitylation in models of basal and luminal human
breast cancer. The sensitivity and speed of the UbiFast method makes it suitable for large-
scale studies in primary tissue samples.
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The post-translational biological process of ubiquitylationattaches the small protein ubiquitin to substrate proteinsthrough the action of a highly coordinated cascade of
activating (E1), conjugating (E2), and ligating (E3) enzymes
believed to number in excess of 600 (refs. 1,2). Ubiquitin is linked
to substrate proteins via its C terminus that forms an isopeptide
bond most often with the epsilon amino group of lysine residues
in the other proteins. Like protein phosphorylation, ubiquityla-
tion is reversible, a process governed by yet another set of over
100 enzymes termed deubiquitinases3,4. The E3 ligases attach
ubiquitin chains to specific substrate proteins, thereby regulating
a wide variety of biological processes, including protein degra-
dation, modulation of substrate activity, and progression through
the cell cycle. Mutations and other changes that result in dysre-
gulation of either ligases or deubiquitinases may lead to aberrant
activation or deactivation of pathways involved in many disease
processes, notably cancer progression and metastasis, immune
disorders, and neurological diseases among others. Their role in
oncogenesis has been well-described4–8. The potential drugg-
ability of E3 ligases with small molecules such as lenalidomide as
treatments for a variety of cancers has greatly increased interest
by the biotechnology and pharmaceutical industries in this class
of enzymes6,9.
While liquid chromatography-mass spectrometry (LC-MS/MS)
is the leading method for unbiased analysis of protein modifica-
tions, comprehensive profiling of endogenous ubiquitylation sites
has, until recently, been very difficult10. The reasons for this
include the large size of the modification (molecular mass of 8.6
kDa), the presence of polyubiquitylated modifications, and the
low stoichiometry of ubiquitylation1,2. The enzyme trypsin is
generally used to generate peptides suitable for proteome analysis
by LC-MS/MS. Proteolysis of ubiquitylated proteins with trypsin
cleaves backbone arginine (Arg) and lysine (Lys) residues in the
substrate protein as well as in the attached ubiquitin; this process
creates tryptic peptides in which the C-terminal Gly–Gly dipep-
tide of ubiquitin is still attached to the side chain of Lys residues
(Fig. 1a). Importantly, the presence of this side-chain modifica-
tion on Lys prevents cleavage at that site by trypsin, thus pro-
ducing a tryptic peptide with an internal modified Lys residue.
Development and commercialization of antibodies that recognize
this di-glycyl remnant (K-ɛ-GG) and enrich these formerly ubi-
quitylated peptides was the breakthrough that made compre-
hensive profiling of ubiquitylation sites by LC-MS/MS possible
(Fig. 1a)10–13.
To enable precise relative quantification of ubiquitylated pep-
tides and sites across differing samples under perturbation con-
ditions, SILAC (Stable Isotope Labeling by Amino Acids in Cell
Culture) has been historically used to differentially label cells
grown in culture prior to antibody enrichment. SILAC enables
comparison of ubiquitylation sites from up to three samples in a
single experiment. We and others have successfully applied this
approach in a range of quantitative biological studies using
metabolically labeled cells6,10,14–18.
Isobaric chemical tags, such as the Tandem Mass Tag (TMT)
system, offer many advantages over SILAC for quantifying post-
translational modifications by mass spectrometry (MS). They
facilitate a decrease in starting material used for enrichment,
enable comparison of 11 or more conditions in a single experi-
ment, and significantly minimize the number of missing peptides
detected and quantified across all experimental conditions relative
to label-free or SILAC-based experiments. However, a major
limitation of the ubiquitylation profiling approach described
above has been that the commercially available antibodies used to
recognize and enrich peptides having the di-glycyl remnant on
the side-chain of lysine do not work when the N-terminus of the
di-glycyl remnant is derivatized with either iTRAQ or TMT.
Efforts to produce antibodies that selectively enrich either an
iTRAQ- or TMT-derivatized K-ɛ-GG peptide and not other
iTRAQ or TMT-labeled peptides have failed to date (unpub-
lished). Until recently this limitation has restricted use of ubi-
quitin profiling to fast growing cell lines that can be metabolically
labeled in culture and has prevented multiplexed, quantitative
analysis of human or animal-derived tissues or primary cell cul-
ture models using isobaric reagents.
To address the need for profiling ubiquitylation sites in tissue
samples, Rose et al.19 introduced a method where samples are
enriched at the peptide level using the anti-K-ɛ-GG antibody
prior to labeling with TMT10 reagents. After elution from the
antibody and labeling, the enriched peptides are subjected to high
pH reversed-phase chromatography using spin columns, frac-
tionated into six fractions, and analyzed by LC-SPS-MS3. In this
study, 5000–9000 ubiquitylated peptides were quantified in cells
using 1 mg sample/TMT label state and in tissue using 7 mg of
sample/TMT label state using 18 h of instrument time. This
approach represented a breakthrough in the ability to employ
isobaric chemical tagging for ubiquitylation profiling of tissues.
However, the large amount of sample and lengthy analysis time
required to achieve significant depth of detection and quantifi-
cation of the ubiquitylome would likely preclude the use of this
approach for analysis of more limited samples such as primary
cells and human tumor samples. These limitations led us to
consider other possible approaches to overcome the inability to
use anti-K-ɛ-GG antibodies with TMT labeling. MS has pre-
viously been used to map the linear amino acid epitope of a
protein recognized by an antibody (Ab)20,21. In these studies,
protein in free and antibody-bound forms was proteolytically
digested and the resulting peptides analyzed by MS. The epitope
was protected from proteolysis when the antibody was bound and
could be identified on the basis of the differential MS analysis.
Inspired by this earlier work, we hypothesized that the di-glycyl
remnant of ubiquitylated peptides would not be solvent exposed
when bound to the anti-K-ɛ-GG antibody.
Leveraging this approach, we here develop a method that
increases both sensitivity and throughput for highly multiplexed
ubiquitylation profiling. In this approach which we term UbiFast,
K-ɛ-GG peptides are labeled with TMT reagents while still bound
to the anti-K-ɛ-GG antibody. By doing so, the amine-reactive,
NHS-ester group of the TMT reagent reacts with the peptide N-
terminal amine group and the ε-amine groups of lysine residues,
but not the primary amine of the di-glycyl remnant. TMT-labeled
K-ɛ-GG peptides from each sample are combined, eluted from
the antibody, and analyzed by single-shot, high-performance LC-
MS/MS (Fig. 1b). We reason that TMT labeling of K-ɛ-GG
peptides bound to the antibody beads could potentially increase
sensitivity, reduce the levels of TMT-based contaminant side-
products, and avoid the need to offline fractionate prior to MS
measurement. We use this method to profile patient-derived
breast cancer xenograft tissue samples in a TMT10-plex experi-
ment using 0.5 mg input/sample to quantify >10,000 distinct
ubiquitylation sites. The method paves the way for quantification
of ubiquitin remnants in human tissues and more physiological
patient-derived cell models where sample amounts are limiting.
Results
Optimization of on-antibody TMT labeling. To establish the
feasibility of labeling peptides with TMT reagents while bound to
the anti-K-ɛ-GG antibody, and to determine the optimal amount
of labeling reagent and labeling time, K-ɛ-GG peptides were
enriched in triplicate from 1mg of Jurkat peptides cells and
labeled with varying amounts of a single TMT reagent for varying
durations while peptides were still bound to antibody (Fig. 1b,
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Supplementary Fig. 1, Supplementary Data 1 and 2). We found
that 10 min labeling with 0.4 mg of TMT reagent provided the
best balance of numbers of identified TMT-labeled K-ɛ-GG
peptides and completeness of labeling (>92%) for K-ɛ-GG pep-
tides bound to anti-K-ɛ-GG antibody. In order to prevent
potential TMT cross-labeling when samples are combined, it is
important that the labeling reaction be fully quenched. Therefore,
we tested quenching of the TMT reactions with 5% hydro-
xylamine. The quenching was successful in stopping the labeling
reaction, evidenced by a slightly reduced labeling efficiency.
Importantly, quenching also increased the number of K-ɛ-GG
peptides identified by almost 10% (Supplementary Fig. 2, Sup-
plementary Data 3a). We find that label-free analysis of enriched
K-ɛ-GG peptides results in lower relative yield of K-ɛ-GG pep-
tides when compared to K-ɛ-GG enrichment coupled to TMT
labeling (Supplementary Fig. 2, Supplementary Data 3b).
Comparison of on-antibody and in-solution TMT labeling. We
next compared in-solution TMT labeling of K-ɛ-GG peptides to
on-antibody TMT labeling of K-ɛ-GG peptides with respect to the
total numbers of K-ɛ-GG peptides detected, the relative yield of
K-ɛ-GG peptides (relative yield is the percentage of K-ɛ-GG
peptides relative to the total peptides identified in the sample) and
the efficiency of TMT labeling (Supplementary Fig. 3a–d,
respectively). Jurkat peptide samples (1 mg, each) were enriched
with the anti-K-ɛ-GG antibody and peptides were labeled with a
single TMT reagent, either while the peptides were bound to the
antibody or using the in-solution labeling method previously
described19 (Supplementary Fig. 3a). On-antibody TMT-labeled
samples resulted in 6087 K-ɛ-GG PSMs with a relative yield of
85.7%, while samples labeled in-solution resulted in 1255 K-ɛ-GG
PSMs with a relative yield of 44.2% (Supplementary Fig. 3b, c,
Supplementary Data 4). The labeling efficiency of on-antibody
and in-solution TMT labeling methods were both high, with 98%
of peptides being at least partially labeled (Supplementary
Fig. 3d).
As both labeling methods are designed to be used with
multiplexed samples, we carried out a head-to-head comparison
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where both labeling methods were used to analyze 10 process
replicates of peptides from HeLa cells, with 1 mg peptide input
per replicate (Supplementary Fig. 4) using single-shot LC-MS/MS
methods with two injections per sample and longer gradients
than in the initial experiments described above (154 vs. 110 min/
injection) totaling to 5.1 h of instrument time. We find that
injecting samples twice leads to a moderate boost in identifica-
tions. In concordance with the single sample experiments, the on-
antibody labeling method identified many more fully quantified,
distinct K-ɛ-GG peptides compared to the in-solution labeling
method (9069 vs. 4587 peptides) (Supplementary Fig. 4b,
Supplementary Data 5a, b). The relative yield of K-ɛ-GG peptides
was 85.4% using the on-antibody labeling approach compared to
49.9% for the in-solution labeling method (Supplementary
Fig. 4b). There was a significant overlap in the commonly
identified sites, with approximately 80% of the sites identified
using the in-solution labeling method also identified by the on-
antibody labeling approach (Supplementary Fig. 4c). The median
CVs between the 10 process replicates were very similar for both
TMT labeling methods (Supplementary Fig. 4d). TMT labeling of
K-ɛ-GG peptides bound to the antibody beads could also
potentially reduce the levels of TMT-based contaminant side-
products in the final sample, which often show up as +1
precursors22, and avoid the need to offline fractionate prior to MS
measurement. Singly charged precursors constituted a far lower
percent of the total precursor ion current using on-antibody TMT
labeling than in-solution labeling (3.9% vs. 16.5% (Supplementary
Fig. 4e, Supplementary Data 5c, d). These results demonstrate
that on-antibody TMT labeling more effectively removes TMT
contaminants and improves K-ɛ-GG enrichment specificity
which is what likely leads to an increase in identified and fully
quantified K-ɛ-GG peptides.
Identification of lenalidomide targets in multiple myeloma. In
prior work, we employed ubiquitylation profiling by MS in
SILAC-labeled multiple myeloma cell lines to reveal the
mechanism of action of lenalidomide, an anti-tumor drug in
multiple myeloma6. This study, which utilized 10 mg of peptide/
SILAC state, revealed that lenalidomide causes degradation of the
Ikaros transcription factors IKZF1 and IKZF3. To benchmark our
approach, we repeated our previously published SILAC-based
experiment by treating MM1S cells with 1 μM lenalidomide for
12 h and MG-132 for 3 h, or with only MG-132 for 3 h using
either HCD-MS2, SPS-MS3 22,23, or FAIMS-MS2, a method
recently shown to increase the numbers of detected and quanti-
fied peptides in proteome studies24,25 (Fig. 2). We then enriched
K-ɛ-GG peptides and carried out on-antibody TMT10 labeling
for ubiquitylome profiling as described above using just 1 mg of
peptide input per sample. The final enriched TMT10-plex sample
mixture was divided into thirds and one-third of the sample was
analyzed by each of the three data acquisition methods (Fig. 2a).
Using the MS2 approach we quantified 15,612 distinct ubiqui-
tylation sites (Fig. 2b, c, Supplementary Data 6a). Using FAIMS-
MS2, the number of quantified ubiquitylated peptides was similar
(15,166) (Supplementary Data 6a). In contrast, only 3970 ubi-
quitylated peptides were observed using SPS-MS3 (Supplemen-
tary Data 6a), more than threefold fewer than using either MS2 or
FAIMS-MS2. The reproducibility of all three methods was high,
with median coefficients of variation across process replicates of
<20% (MS2: 13.2%, FAIMS-MS2:15.8%, SPS-MS3: 10%).
Using either MS2 or FAIMS-MS2, we observed the expected
changes in ubiquitylation induced by lenalidomide treatment
on multiple lysine residues of IKZF1, IKZF3, and CSNK1A1.
Because IKZF1 and IKZF3 are rapidly ubiquitylated and targeted
for degradation, the resulting decrease in corresponding
ubiquitylated peptides is a result of decreased absolute levels of
these proteins6. However, using SPS-MS3, changes in ubiquityla-
tion of one of the key transcription factors, IKZF1, were not
detected, and fewer ubiquitylated peptides overall were detected
on the IKZF3 and CSNK1A1 (Fig. 2d). Importantly, the expected
ubiquitylated and degraded proteins were identified using only 1
mg peptide/sample compared to a total of 10 mg input/sample
used in the SILAC approach6. Together, these results support the
feasibility and value of multiplexed ubiquitylation profiling in
systems where sample amounts are limiting.
Accuracy of ubiquitylated peptide quantification. Using
HCD-MS2 we observed several ubiquitylated peptides from
IKZF1, IKZF3, and CSNK1A1 that appeared to not be sig-
nificantly down-regulated upon lenalidomide treatment despite
the observation of other ubiquitylated peptides from these
same proteins that were strongly regulated (Supplementary
Fig. 5a). We reasoned that this was most likely the result of
ratio compression, an expected and well-described issue related
to TMT quantitation22,26. Precursor isolation purity filtering is
a common approach for removing interferences in TMT
experiments27,28. Filtering MS2 (Supplementary Fig. 5b, Sup-
plementary Data 6b) and FAIMS-MS2 data (Supplementary
Data 6b) for only those peptides having >90% precursor iso-
lation purity (PIP) significantly improved quantification
accuracy while decreasing the total number of ubiquitylated
peptides observed in MS2 by 40.8% (Supplementary Data 6b).
As expected, FAIMS-MS2 reduced precursor co-isolation
interference and stringent PIP filtering retained relatively
more ubiquitylated peptides than stringent PIP filtering of MS2
data, reducing the total number of ubiquitylated peptides by
only 28% (Supplementary Fig. 5c, Supplementary Data 6b).
SPS-MS3 had the greatest accuracy, but identified fewer of the
statistically significant sites that were seen by either MS2 and
FAIMS-MS2 (Supplementary Fig. 5d, Supplementary Data 6).
Applying UbiFast for rapid profiling of tumor tissue. To
demonstrate the utility of the UbiFast approach to quantitatively
profile the ubiquitylome of small amounts of tissue, we isolated
tumors from two previously described breast cancer patient-
derived xenograft (PDX) models, representing basal (WHIM2)
and luminal (WHIM16) subtypes of breast cancer, respectively29
(Fig. 3a). These models faithfully reproduce genomic features of
the disease, exhibiting distinct expression of key basal and
luminal genes, and proteome-driven basal and luminal pathway
signatures30. Ubiquitylated peptides were enriched from five
replicates each of WHIM2 and WHIM16 using 0.5 mg of peptide
per sample. As described above, peptides enriched using anti-K-ɛ-
GG antibody were TMT labeled on antibody. TMT-labeled
peptides from each sample were then combined and analyzed
using two single-shot LC-MS/MS runs. FAIMS was used with two
compensation voltage (CV) sets per injection (see Methods) to
reduce ratio compression and increase the total number of ubi-
quitylated peptides identified. We find that injecting samples
twice using a different compensation voltage set for each analysis
results in lower peptide overlap (and therefore higher total
identifications) relative to two independent injections without
FAIMS. A total of 13,501 human K-ɛ-GG peptides were observed,
81% (10,942) of which were quantified across all 10 TMT chan-
nels (Supplementary Data 7a). The correlation across replicates
was high, with a median Pearson correlation of 0.78–0.81
(Fig. 3b).
To identify the relationship between ubiquitylated peptides and
their protein expression, we compared our ubiquitylome dataset to
a previously published deep-scale proteomics dataset obtained on
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the same basal and luminal PDX breast cancer models that used a
similar TMT10 design with analysis of 24 offline basic reverse
phase fractions (vs. UbiFast using single-shot methods) using a
similar TMT10 workflow31 (Supplementary Data 7c). There was a
high degree of correlation between the fold-changes observed
between basal and luminal expression at the level of K-ɛ-GG
modified peptides and the corresponding protein abundance
changes. This further supports robust quantification of ubiqui-
tylated peptides relative to deep-scale fractionated proteome as it
is expected that the majority of changes observed in the
ubiquitylome will be driven by changes in the levels of the
corresponding proteins (Pearson correlation= 0.6) (Fig. 3c).
However, in addition, we also identified a total of 801 K-ɛ-GG
peptides that were regulated (log2 fold-change >1 and <−1)
primarily at the level of ubiquitylation (referred to as Ubi-
regulated), but that did not show regulation at the protein level
(log2 fold-change >−0.3 and <0.3) (Fig. 3c, Supplementary
Data 7,d). A total of 110 sites showed marked outlier regulation
with log2 fold-change >2 and <−2 (Fig. 3c, Supplementary
Data 7d). Of note, we observed differential ubiquitylation of 15 E3
ligases; TRAF7, HUWE1, NEDD4L, UBE3A, UBE4B, CBL,
BIRC6, RAD18, RNF146, MIB1, HERC2, and AFF4 showed
upregulated ubiquitylation in Basal subtype whereas ITCH,
TRIM25, RNF185, and IRF2BPL showed upregulated ubiquityla-
tion in Luminal PDX model (Supplementary Data 7,d). Pathway
enrichment of Ubi-regulated proteins (Fig. 3d) showed enrich-
ment of several immune-signaling pathways in the basal PDX
models consistent with the critical role of ubiquitylation in
immune signaling14,32,33. Interestingly, Basal or triple-negative
breast cancer shows high immunological activity and are
attractive candidates for immuno-oncology therapies34 and,
therefore, upregulated ubiquitylation of immune signaling is
consistent with the “immune hot” environment within the basal
PDX tumor.
To begin to evaluate the crosstalk between two distinct lysine
modifications, we compared differential ubiquitylation and
acetylation (K-Ac) in these basal and luminal PDX models
(Supplementary Fig. 6, Supplementary Data 7c). Enrichment of
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K-Ac peptides was performed35. TMT-labeled peptides from five
replicates each of the basal and luminal PDX models were mixed
at an equal ratio, fractionated into four fractions and subjected to
immuno-enrichment using an anti-acetyl antibody (PTM-SCAN
acetyl-kit; Cell Signaling Technologies). A total of 11,929
acetylated peptides were identified with 10,967 of these identified
across all channels. Over 2550 sites showed both acetylation and
ubiquitylation with Pearson correlation of 0.45 (Supplementary
Fig. 6a, b, Supplementary Data 7d). Interestingly, a small subset of
Ubi-regulated sites were also inversely regulated by acetylation
suggesting a regulatory crosstalk between ubiquitylation and
acetylation (Supplementary Fig. 6c, d). In summary, this study
highlights the feasibility of UbiFast to identify ubiquitylation
driven pathways in tumors as well as cell lines, and that it can also
be used to investigate the crosstalk of lysine ubiquitylation and
other lysine modifications such as acetylation as exemplified in
this study. Future studies in a larger number of PDX or human
tumors are needed to elucidate in vivo functional roles.
Discussion
A major advantage of TMT-based quantitation is the ability to
analyze a variety of sample types including primary tissue.
However, to realistically monitor ubiquitylation in human cancer
tissue and patient-derived cell culture models where generation of
protein input of >1 mg/sample is not feasible, a highly sensitive
method that can be successfully employed in the 500 μg–1 mg
range is needed. With this in mind, we have developed a method
for rapid, sensitive and multiplexed ubiquitylation profiling in
cells and tissue using anti-K-ɛ-GG antibodies to enrich ubiqui-
tylated peptides followed by on-antibody TMT labeling. We
directly compared on-antibody TMT labeling to conventional in-
solution TMT labeling of enriched K-ɛ-GG peptides and
demonstrated that TMT labeling of K-ɛ-GG peptides while
bound to the antibody significantly increases sensitivity, due in
part to a significant reduction in the level of TMT contaminant
side-products in the final processed sample. We have used this
method to quantify over 11,000 ubiquitylated peptides from as
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Fig. 3 Ubiquitylation analysis of breast cancer PDX models. a Schematic diagram showing experimental design used to enrich di-Gly modified peptides
from the Luminal and Basal breast cancer PDX models. b Pearson correlation between Luminal and Basal PDX replicates (n= 5 process replicates). Boxplot
depicts upper and lower quartiles, with median shown as a solid line. Whiskers show 1.5 interquartile range. Source Data are provided in Supplementary
Data 7a. c Scatter plot showing log2 fold-change between Basal and Luminal PDXs, for expression of ubiquitylated sites and the corresponding protein. The
proteins that were upregulated or down-regulated exclusively at the level of their ubiquitylation are indicated by red or blue points, respectively. d Pathway
enrichment of proteins regulated primarily at the level of ubiquitylation.
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little as 500 μg input using only 5.1 h of instrument time,
demonstrating that the method is suitable for large-scale studies
in primary tissue samples.
Relative to our previously published SILAC-based method for
ubiquitylation profiling, the UbiFast method enables multiplexing
of >3x more samples, uses 6–12x less peptide input per treatment
condition, requires much less wet lab processing time, and utilizes
5x less LC-MS measurement time11. Additionally, we find that
on-antibody TMT labeling increases the relative yield of K-ɛ-GG
peptides relative to SILAC, label free (Supplementary Fig. 2), and
in-solution TMT labeling-based methods. Because of these
complexities and inefficiencies in using the SILAC quantification
approach for ubiquitylation profiling in cells noted above, studies
focused on identifying drug-induced substrates of E3 ubiquitin
ligases are being carried out with increasing frequency by pro-
teome profiling only rather than ubiquitin profiling36,37. The
simplicity and speed of our on-antibody labeling approach opens
the door to deep-scale ubiquitylation profiling to more directly
identify the substrates of E3 ligases degraded by the proteasome
degradation pathway. Combined with proteome profiling, the
UbiFast method should facilitate identification of signaling effects
of ubiquitylation as well as substrates of proteasomal degradation.
The acetylome and ubiquitylome data sets we provide on the
breast cancer xenograft samples are a rich source for the com-
munity to begin to probe and elucidate signaling crosstalk
between acetylation and ubiquitylation.
A current limitation of the UbiFast method is that the depth of
quantification appears to be limited to around 10,000 sites/sample
when starting with 0.5–1 mg of sample/TMT channel. While this
depth-of-coverage is less than what is achieved in SILAC-based
experiments, the input amount requirements are lower, the mul-
tiplexing capacity is significantly higher, and the method requires
no offline fractionation, making it faster and far easier to imple-
ment. This is approximately the same depth of coverage achieved
using acetylome profiling, but is substantially less than phospho-
profiling that can produce over 35,000 distinct phosphosites/
sample in a 10-plex experiment30. Extension of our method to
higher-plex isobaric labeling methods such as TMTPro (Thermo
Fisher) that enables 16-plex analysis should allow further reduc-
tion in the amount of sample/channel needed to achieve current
depth of analysis. In addition, the quantitative accuracy of the
FAIMS-MS2 data generation method we employ is somewhat
lower than can be achieved using SPS-MS3, but the lower accuracy
is compensated for by the much higher numbers of sites quantified
and able to be shown to be differential between states. Future
efforts will also be aimed at reducing the amount of labeling
reagent required for on-antibody TMT labeling to further reduce
the cost of the UbiFast method. Zecha et al.31 have recently pre-
sented a protocol for TMT labeling that reduces the quantity of
required labeling reagent by reducing reaction volumes.
Beyond applications for ubiquitylation profiling, we hypothe-
size that on-antibody TMT labeling will be a valuable method to
increase the throughput and lower the TMT reagent cost for
multiplexed analysis of other PTMs requiring antibody-based
enrichment such as lysine acetylation and tyrosine phosphor-
ylation. The UbiFast method is also potentially amenable to serial
enrichment analysis workflows38 which is especially important
when sample amounts are limiting. Finally, we envision that the
ease and simplicity of the UbiFast method may be transferable to
automated robotic sample-handling platforms to facilitate pro-
cessing of very large numbers of samples for ubiquitylome
analyses39.
Methods
Ethical compliance. PDX models used in this study were approved by the insti-
tutional animal care and use committee at Washington University in St. Louis.
Anti-K-ɛ-GG antibody crosslinking. For all experiments, the PTM-Scan ubiquitin
remnant motif (K-ɛ-GG) kit (Cell Signaling Technology, Kit #5562) was cross-
linked. Briefly, antibody-bound beads were washed three times with 100 mM
sodium borate (pH 9.0) and incubated with 20 mM DMP for 30 min at room
temperature. Beads were washed 2× with 200 mM ethanolamine and incubated
overnight at 4 °C with 200 mM ethanolamine. Following this incubation, beads
were washed 3× with immunoprecipitation (IAP) buffer (50 mM MOPS, pH 7.2,
10 mM sodium phosphate, 50 mM NaCl) and stored at 4 °C at a concentration of
0.5 μg/μL.
Optimization of TMT reagent amount and labeling time. Jurkat cells, clone E6-1
obtained from ATCC (TIB-152) were cultured in RPMI-1640 media (Invitrogen)
supplemented with 10% dialyzed fetal bovine serum (Sigma-Aldrich), penicillin/
streptomycin, and L-glutamine (Invitrogen). Cells were lysed for 30 min with ice
cold urea lysis buffer containing 8 M urea, 75 mM NaCl, 50 mM Tris-HCl (pH 8.0),
1 mM EDTA, 2 μg/mL Aprotinin (Sigma), 10 μg/mL Leupeptin (Roche), 1 mM
PMSF (Sigma). Samples were spun at 20,000 g for 10 min and a BCA assay
(Thermo Fisher) was used to determine the concentration of protein in each
cleared lysate. Lysis buffer was used to equalize the protein concentration of each
lysate to 8 mg/mL. Protein disulfide bonds were reduced with 5 mM dithiothreitol
(Thermo Fisher) at 25 °C for 45 min. The proteins were alkylated in the dark using
10 mM iodoacetamide at 25 °C for 45 min. Lysates were then diluted 1:4 using
50 mM Tris, pH 8.0, to lower the urea concentration to 2 M. LysC (Wako) was
added to each lysate at a 1:50 enzyme-to-substrate ratio and samples were digested
at 25 °C for 2 h. Following LysC digestion, Trypsin (Promega) was added at a 1:50
enzyme-to-substrate ratio and the samples were digested at 25 °C overnight. The
digestion was quenched with 100% formic acid to reach a volumetric concentration
of 1% formic acid. Samples were spun at 5000 g for 5 min to remove precipitated
urea and then desalted using Sep-Pak C18 columns (Waters, 500 mg WAT043395).
Sep-Pak columns were conditioned with 1 × 5mL 100% acetonitrile (ACN), 1 ×
5 mL 50% ACN/0.1% formic acid (FA), and 4 × 5 mL 0.1% trifluoroacetic acid
(TFA). Each sample was loaded onto a column and washed with 3 × 5 mL 0.1%
TFA and 1 × 5 mL 1% FA. Peptides were eluted off the column with 2 × 3 mL 50%
ACN/0.1% FA and dried down. Peptides were resuspended in 3% ACN, 0.1% FA
and a BCA assay (Thermo Fisher) was used to determine the concentration of
peptide in each sample. Samples were then aliquoted into 1 mg aliquots, dried
down and stored at −80 °C.
For each replicate enrichment, 1 mg of Jurkat peptide sample and 31.25 μg of
crosslinked anti-K-ɛ-GG antibody was used. Specifically, 31.25 μg of crosslinked
anti-K-ɛ-GG antibody from 0.5 μg/μL solution was pipetted into 1.5 mL Eppendorf
tubes. one milligram of Jurkat peptide was resuspended in 1.5 mL of IAP buffer and
shaken at room temperature (RT) for 5 min. The pH of each Jurkat peptide sample
was checked by spotting ~1 μL of solution on pH paper to ensure the pH was ~7. If
the pH was acidic, the samples were titrated using 1M Tris. Peptide samples were
then centrifuged at 5000 g for 5 min. Jurkat peptides were added to a tube of
aliquoted antibody and incubated for 1 h at 4 °C, with gentle end-over-end
rotation. After incubation, all enrichments were kept on ice unless being handled.
Following incubation, all samples were centrifuged at 2000 r.c.f. for 1 min and then
antibody beads were allowed to settle by letting tubes sit for ~10–20 s on ice. The
supernatant (IP flowthrough) was removed and the antibody beads were washed
with 1.5 mL of ice cold IAP buffer. For washing the beads, after the addition of the
wash reagent, the tubes were inverted ~5 times, centrifuged for ~30–60 s at 2000
r.c.f., allowed to sit for ~10–20 s to let the beads settle, and the supernatant was
removed. All washes were completed as quickly as possible. A wash with 1.5 mL of
ice cold PBS was performed and antibody beads were resuspended in 200 μL of
100 mM HEPES (pH 8.5).
For optimization of on-antibody TMT labeling, TMT reagent amount (data
shown in Supplementary Fig. 1a, b) and TMT labeling time were tested (data
shown in Supplementary Fig. 1b, c). For experiments testing TMT reagent amount,
0.8 mg, 0.4 mg, or 0.2 mg of a single TMT10 reagent (Thermo Fisher) was
resuspended in 10 μL of ACN and added to each enrichment sample, samples were
spun down quickly at 2000 r.c.f. for 5–10 s, and samples were incubated at RT for
5 min shaking at 1400 r.p.m. For experiments testing TMT labeling time, 0.4 mg of
a single TMT10 reagent was resuspended in 10 μL of ACN and added to each
enrichment sample, samples were spun down quickly at 2000 r.c.f. for 5–10 s, and
samples were incubated at RT for 5, 10, or 20 min shaking at 1400 r.p.m.
Following the TMT incubation step, samples were washed with 1.3 mL of ice
cold IAP buffer followed by 1.5 mL ice cold IAP buffer, and 1.5 mL of ice cold PBS.
The final wash buffer was removed and the enriched peptides were eluted from the
antibody beads by adding 150 μL of 0.15% TFA to the beads forcefully enough to
resuspend them and incubating for ~5 min at RT. While the beads were incubating
in elution buffer, StageTips containing 2 Empore C18 (3 M) punches were
conditioned and equilibrated with 1 × 100 μL methanol (MeOH), 1 × 100 μL 50%
ACN/0.1% FA, and 2 × 100 μL 0.1% FA.
After elution of enriched peptides from anti-K-ɛ-GG antibody, samples were
spun down for 30 s at 2000 r.c.f. and the supernatant containing the eluted peptides
was removed from the beads and added directly to a conditioned StageTip. Extra
care was taken to not pipette antibody beads. A second elution of peptides from the
antibody beads was performed exactly as described above. During the second
elution incubation, the supernatant of the first elution was spun through the
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conditioned StageTips at 3500 r.c.f. for 2 min. After the second elution incubation
was completed, the tubes were spun down for 30 s at 2000 r.c.f., the supernatants
were loaded onto the StageTips, and supernatant was spun through at 3500 r.c.f. for
2 min. StageTips were washed with 2 × 100 μL 0.1% FA. Peptides were eluted from
StageTips with 1 × 50 μL 50% ACN/0.1% FA and transferred to HPLC vials and
dried to completion.
Peptides were reconstituted in 9 μL of 3% MeCN/0.1% FA and analyzed by
online nanoflow LC-MS/MS using a Q-Exactive+ mass spectrometer (Thermo
Fisher Scientific) coupled online to an Easy-nLC 1000 (Thermo Fisher Scientific).
Briefly, 4 μL of sample was loaded onto a microcapillary column (360 μm OD × 75
μm ID) containing an integrated electrospray emitter tip (10 μm) (New Objective)
packed with 24 cm of ReproSil-Pur C18-AQ 1.9 μm beads (Dr. Maisch GmbH).
The nanoflow column was heated to 50 °C using a column heater (Phoenix S&T).
Samples were analyzed using a 110 min LC-MS method. Mobile phase flow rate
was 200 nL/min. Solvent A comprised 3% acetonitrile/0.1% FA. Solvent B
comprised 90% acetonitrile/0.1% FA. The LC-MS/MS method used the following
gradient profile: (min:%B) 0:2; 1:6; 85:30; 94:60; 95:90; 100:90; 101:50; 110:50 (the
last two steps at 500 nL/min flow rate). The mass spectrometer was operated such
that MS1 spectra were measured with a resolution of 70,000, an AGC target of 3 ×
106, and a mass range from 300 to 1800 m/z. The top 12 most abundant precursors
were triggered for MS/MS at a resolution of 35,000, an AGC target of 5 × 104, an
isolation window of 0.7 m/z, a maximum ion time of 150 ms, and a normalized
collision energy of 30. The dynamic exclusion time was set to 20 s, the peptide
match was set to preferred, and charge state screening was enabled to reject
precursor charge states that were unassigned, 1, or >6.
Quenching of on-antibody TMT labeling reactions. To test the feasibility of
quenching TMT reactions for on-antibody labeling, replicate 1 mg aliquots of
Jurkat peptides were prepared and enriched with anti-K-ɛ-GG antibody exactly as
described above. On-antibody TMT labeling was completed using 0.4 mg of a
single TMT10 reagent for 10 min exactly as described above. Quenching was
performed after the TMT incubation step by adding 8 μL of 5% hydroxylamine to
each sample, spinning down quickly at 2000 r.c.f. for 5–10 s, and shaking samples
at RT for 5 min at 1400 r.p.m. Sample washing post TMT incubation, peptides
elution from the antibody, desalting, and LC-MS/MS analysis were performed
exactly as described above for TMT reagent amount and reaction time
optimizations.
Comparison of on-antibody and in-solution TMT labeling. To compare results
of on-antibody and in-solution TMT labeling, replicate 1 mg aliquots of Jurkat
peptides were enriched and labeling by each respective method.
For on-antibody labeling, Jurkat peptides were prepared, incubated with anti-K-
ɛ-GG antibody beads, TMT labeled with 0.4 mg TMT10 reagent for 10 min, and
quenched exactly as described above for TMT quenching experiments. After
quenching, samples were washed 4 × 1.5 mL ice cold IAP buffer followed by 1 ×
1.5 mL ice cold PBS. The final wash buffer was removed and samples were eluted,
desalted, and analyzed by LC-MS/MS as described for TMT reagent amount and
reaction time optimization.
For in-solution TMT labeling, Jurkat peptides were prepared and incubated
with anti-K-ɛ-GG antibody beads exactly as described for TMT reagent amount
and reaction time optimization. Following incubation, all samples were centrifuged
at 2000 r.c.f. for 1 min and then antibody beads were allowed to settle by letting
tubes sit for ~10–20 s on ice. The supernatant (IP flowthrough) was removed and
the antibody beads were washed with 3 × 1.5 mL of ice cold IAP buffer and 2 ×
1.5 mL ice cold PBS. Samples were then eluted with 0.15% TFA and desalted with
StageTips exactly as described for TMT reagent amount and reaction time
optimization experiments. After elution from StageTips, peptides were kept in
1.5 mL tubes and dried to completion.
Dried K-ɛ-GG peptides were resuspended in 18 μL of 200 mM HEPES. Four
microliters of 100% ACN was added. TMT labeling was performed by adding 3 μL
of a TMT10 reagent (0.8 mg/41 μL) to each sample and shaking samples at RT for
1 h at 700 r.p.m. TMT labeling was quenched by adding 2 μL of 5% hydroxylamine
to each sample and shaking samples at RT for 15 min at 700 r.p.m. Samples were
acidified with 2.7 μL 10% FA and dried to completion.
Dried labeled K-ɛ-GG peptides were resuspended in 150 μL 0.1% FA. StageTips
containing 2 Empore C18 (3 M) punches were conditioned and equilibrated with
1 × 100 μL methanol (MeOH), 1 × 100 μL 50% ACN/0.1% FA, and 2 × 100 μL 0.1%
FA. The resuspended peptides were loaded onto the StageTips, and spun through at
3500 r.c.f. for 2 min. The StageTips were washed with 2 × 100 μL 0.1% FA. Peptides
were eluted with 1× 50 μL 50% ACN/0.1% FA. Eluted peptides were transferred to
HPLC vials and dried to completion. LC-MS/MS analysis was performed as
described for TMT reagent amount and reaction time optimization.
On-antibody vs in-solution labeling for a TMT10 experiment. HeLa S3 cells
(ATCC CCL-2.2) were cultured in RPMI-1640 media (Invitrogen) supplemented
with 5% dialyzed fetal bovine serum (Sigma-Aldrich), penicillin, streptomycin, and
glutamine (Invitrogen). HeLa tryptic peptides were generated exactly as described
above for Jurkat cells. To generate data shown in Supplementary Fig. 4, two dif-
ferent TMT10-plex experiments were completed, each containing 10 × 1mg
peptide process replicates as input per TMT channel. One TMT10-plex experiment
was used to test on-antibody TMT labeling following K-ɛ-GG peptide enrichment
and the other plex was used to test in-solution TMT labeling following K-ɛ-GG
peptide enrichment.
For the on-antibody TMT10-plex experiment 31.25 μg of crosslinked anti-K-ɛ-
GG antibody from 0.5 μg/μL solution was pipetted into 10 × 1.5 mL Eppendorf
tubes. Each 1 mg peptide sample was resuspended in 1.5 mL of IAP buffer and
shaken at room temperature (RT) for 5 min. The pH of each sample was checked
by spotting ~1 μL of solution on pH paper to ensure the pH was ~7. If the pH was
acidic, the samples were titrated using 1 M Tris. Peptide samples were then
centrifuged at 5000 r.c.f. for 5 min. Each sample was added to its own tube of
aliquoted antibody and incubated for 1 hr at 4 °C, with gentle end-over-end
rotation. After incubation, all enrichments were kept on ice unless being handled or
centrifuged. Following incubation, all samples were centrifuged at 2000 r.c.f. for
1 min and antibody beads were allowed to settle by letting tubes sit for ~10–20 s on
ice. The supernatant (IP flowthrough) was removed and the antibody beads were
washed with 1.5 mL of ice cold IAP buffer. For washing the beads, after the
addition of the wash reagent, the tubes were inverted ~5 times, centrifuged for
~30–60 s at 2000 r.c.f., allowed to sit for ~10–20 s to let the beads settle, and the
supernatant was removed. All washes were completed as quickly as possible. A
wash with 1.5 mL of ice cold PBS was performed and antibody beads were
resuspended in 200 μL of 100 mM HEPES (pH 8.5).
On-antibody TMT labeling was performed by adding 0.4 mg of the appropriate
TMT10 reagent (resuspended in 10 μL of ACN) to each enrichment sample.
Samples were spun down quickly at 2000 r.c.f. for 5–10 s and incubated at RT for
10 min while shaking at 1400 r.p.m. Quenching of the TMT labeling reaction was
performed by adding 8 μL of 5% hydroxylamine to each sample, spinning down
quickly at 2000 r.c.f. for 5–10 s, and shaking samples at RT for 5 min at 1400 r.p.m.
Following quenching, samples were washed with 1.3 mL ice cold IAP buffer
followed by 1.5 mL ice cold IAP buffer. Next, 130 μL of ice cold IAP buffer was
added to each tube and used to resuspend the antibody beads. All the antibody
beads from each tube were transferred and combined in a new 1.5 mL tube.
Combined antibody beads were washed with the IAP buffer used for the bead
transfer. The empty tubes previously containing antibody beads were serially
washed once with 1.5 mL ice cold IAP buffer. Afterwards, the combined antibody
beads were washed with this IAP buffer. Combined antibody beads were washed
once with 1.5 mL ice cold PBS.
The final wash buffer was removed and peptides were eluted from the antibody
beads by adding 150 μL of 0.15% TFA to the beads forcefully enough to resuspend
them and incubating for ~5 min at RT. While the beads were incubating in elution
buffer, a StageTip containing 2 Empore C18 (3M) punches was conditioned and
equilibrated with 1 × 100 μL methanol (MeOH), 1 × 100 μL 50% ACN/0.1% FA,
and 2 × 100 μL 0.1% FA. After elution of enriched peptide from the anti-K-ɛ-GG
antibody, the combined sample was spun down for 30 s at 2000 r.c.f. and the
supernatant containing the eluted peptides was removed from the beads and added
directly to the conditioned StageTip. Extra care was taken to not pipette antibody
beads. A second elution of peptides from the antibody beads was performed exactly
as described above. During the second elution incubation, the supernatant of the
first elution was spun through the StageTip at 3500 r.c.f. for 2 min. After the second
elution incubation was completed, the tube with combined antibody beads was
spun down for 30 s at 2000 r.c.f., the supernatant was loaded onto the StageTip, and
supernatant was spun through at 3500 r.c.f. for 2 min. The StageTip was washed
with 2 × 100 μL 0.1% FA. Peptides were eluted with 1 × 50 μL 50% ACN/0.1% FA.
Eluted peptides were transferred to an HPLC vial and dried to completion.
Peptides were reconstituted in 9 μL of 3% MeCN/ 0.1% FA and analyzed by
online nanoflow LC-MS/MS using an Easy-nLC1200 coupled to an Orbitrap
Fusion Lumos (Thermo Fisher Scientific) mass spectrometer. Briefly, 4 μL of
sample was loaded onto a microcapillary column (360 μm OD × 75 μm ID)
containing an integrated electrospray emitter tip (10 μm) (New Objective) packed
with 24 cm of ReproSil-Pur C18-AQ 1.9 μm beads (Dr. Maisch GmbH). The
nanoflow column was heated to 50 °C using a column heater (Phoenix S&T).
Samples were analyzed using a 154 min LC-MS method. Mobile phase flow rate
was 200 nL/min. Solvent A comprised 3% acetonitrile/0.1% FA. Solvent B
comprised 90% acetonitrile/0.1% FA. The LC-MS/MS method used the following
gradient profile: (min:%B) 0:2; 1:6; 122:35; 130:60; 133:90; 143:90; 144:50; 154:50
(the last two steps at 500 nl/min flow rate). The mass spectrometer was operated
such that MS1 spectra were measured with a resolution of 60,000, an AGC target of
4 × 105, and a mass range from 350 to 1800 m/z. A top speed approach (cycle time
2 s) was used to trigger MS/MS at a resolution of 50,000, an AGC target of 1 × 105,
an isolation window of 0.7 m/z, a maximum ion time of 150 ms, and a normalized
collision energy of 38. The dynamic exclusion time was set to 20 s, the peptide
match was set to peptide mode, and charge state screening was enabled to reject
precursor charge states that were unassigned, 1, or >6.
For the in-solution TMT10-plex experiment, the 10 × 1 mg HeLa peptide
samples were prepared and incubated with anti-K-ɛ-GG antibody as described for
the on-antibody TMT10-plex above. Following incubation, all 10 samples were
centrifuged at 2000 r.c.f. for 1 min and antibody beads were allowed to settle by
letting tubes sit for ~10–20 s on ice. The supernatant (IP flowthrough) was
removed and the antibody beads were washed with 3 × 1.5 mL ice cold IAP buffer,
2 × 1.5 mL ice cold PBS. After removing the final wash buffer, all 10 samples were
eluted with 0.15% TFA acid and individually desalted with StageTips containing 2
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Empore C18 (3 M) punches as described above for the on-antibody TMT10-plex
method. After elution from StageTips, peptides were kept in 1.5 mL tubes and dried
to completion.
Each of the 10 dried K-ɛ-GG peptide samples were resuspended in 18 μL of
200 mM HEPES. Once resuspended, 4 μL of 100% ACN was added to each sample.
TMT labeling of each sample was performed by adding 3 μL of the appropriate
TMT10 reagent (0.8 mg/41 μL) to each sample followed by shaking at RT for 1 h at
700 r.p.m. TMT labeling was quenched by adding 2 μL of 5% hydroxylamine to
each sample and shaking samples at RT for 15 min at 700 r.p.m. All samples were
combined into a single tube, acidified by adding 3 μL of 100% FA, and dried to
completion.
Dried labeled K-ɛ-GG peptides were resuspended in 150 μL 0.1% FA. A
StageTip containing 2 Empore C18 (3 M) punches was conditioned and
equilibrated with 1 × 100 μL methanol (MeOH), 1 × 100 μL 50% ACN/0.1% FA,
and 2 × 100 μL 0.1% FA. The resuspended peptides were loaded onto the StageTip,
and spun through at 3500 r.c.f. for 2 min. The StageTip was washed with 2 × 100 μL
0.1% FA. Peptides were eluted with 1× 50 μL 50% ACN/0.1% FA. Eluted peptides
were transferred to HPLC vials and dried to completion. LC-MS/MS analysis was
performed using the exact parameters described above for the on-antibody
TMT10-plex method.
Ubiquitylation profiling of lenalidomide-treated cells. MM1S cells (ATCC
#2974) were cultured in RPM1-1640 (Invitrogen) supplemented with 10% dialyzed
fetal bovine serum (Sigma-Aldrich), penicillin, streptomycin, and glutamine
(Invitrogen). Cells were treated for 12 h with 1 μM lenalidomide (Selleck) and for
3 h with 5 μM MG-132 (Selleck) or treated with only 5 μM MG-132 for 3 h. MM1S
cells were lysed for 30 min with ice cold urea lysis buffer containing 8 M urea,
75 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 2 μg/mL Aprotinin (Sigma,
A6103), 10 μg/mL Leupeptin (Roche #11017101001), 1 mM PMSF (Sigma, 78830),
1 mM CAM (Sigma, 22790), and 50 μM PR-619 (LifeSensors, SI9619). Tryptic
peptides were generated exactly as described above for Jurkat cells. For the TMT10-
plex experiment shown in Fig. 2, five channels consisted of process replicates from
lenalidomide+MG-132-treated samples and the other five channels consisted of
process replicates from MG-132-treated samples. An input of 1 mg peptide was
used for each experimental condition. K-ɛ-GG peptide enrichment and on-
antibody TMT labeling was completed exactly as described above for the TMT10-
plex HeLa cell experiment.
The final TMT10 K-ɛ-GG-enriched sample was reconstituted in 14 μL of 3%
MeCN/ 0.1% FA and analyzed on a Fusion Lumos mass spectrometer (Thermo
Fisher Scientific) coupled online to an Easy-nLC1200 (Thermo Fisher Scientific).
One-third of the sample was analyzed by HCD-MS2, another one-third by FAIMS-
HCD-MS2, and the final one-third by SPS-MS3.
MS2 data were acquired using the following method: 4 μL of sample was loaded
onto a microcapillary column (360 μm OD × 75 μm ID) containing an integrated
electrospray emitter tip (10 μm) (New Objective) packed with 24 cm of ReproSil-
Pur C18-AQ 1.9 μm beads (Dr. Maisch GmbH). The nanoflow column was heated
to 50 °C using a column heater (Phoenix S&T). Samples were analyzed using a 154
min LC-MS method. Mobile phase flow rate was 200 nL/min. Solvent A comprised
3% acetonitrile/0.1% FA. Solvent B comprised 90% acetonitrile/0.1% FA. The LC-
MS/MS method used the following gradient profile: (min:%B) 0:2; 1:6; 122:35;
130:60; 133:90; 143:90; 144:50; 154:50 (the last two steps at 500 nl/min flow rate).
The mass spectrometer was operated such that MS1 spectra were measured with a
resolution of 60,000, an AGC target of 4 × 105, and a mass range from 350 to 1800
m/z. A top speed approach (cycle time 2 s) was used to trigger MS/MS at a
resolution of 50,000, an AGC target of 5 × 104, an isolation window of 0.7 m/z, a
maximum ion time of 150 ms, and a normalized collision energy of 34. The
dynamic exclusion time was set to 20 s, the peptide match was set to peptide mode,
and charge state screening was enabled to reject precursor charge states that were
unassigned, 1, or >6.
FAIMS-MS2 data were acquired using the following method: 4 μL of sample
was loaded onto the same microcapillary column (360 μm OD × 75 μm ID) that
was used to acquire the MS2 and SPS-MS3 data using the same HPLC settings
described for the HCD-MS2 method above. The mass spectrometer was operated
such that MS1 spectra were measured with a resolution of 60,000, an AGC target of
4 × 105, and a mass range from 300 to 1800 m/z. The Thermo FAIMS Pro device
was run with default parameters. The FAIMS source was operated in standard
resolution mode at 100 °C. FAIMS compensation voltages (CVs) of 40, 60, and
80 V were used with a top10 method to trigger MS/MS at a resolution of 50,000, an
AGC target of 5 × 104, an isolation window of 0.7 m/z, a maximum ion time of
150 ms, and a normalized collision energy of 34. The dynamic exclusion time was
set to 20 s, the peptide match was set to peptide mode, and charge state screening
was enabled to reject precursor charge states that were unassigned, 1, or >6.
SPS-MS3 data were acquired using the following method: 4 μL of sample was
loaded onto the same microcapillary column (360 μm OD × 75 μm ID) that was
used to acquire the MS2 and FAIMS-MS2 data using the same HPLC settings
described for the HCD-MS2 method above. The mass spectrometer was operated
such that MS1 spectra were measured with a resolution of 60,000, an AGC target of
4 × 105, and a mass range from 300 to 1800 m/z. The top 10 most abundant ions
from the MS1 scan were method to trigger MS/MS in the Orbitrap at a resolution
of 15,000, an AGC target of 5 × 104, a maximum ion time of 300 ms, and an
isolation width of 0.5, using a normalized CID collision energy of 35%. A
synchronous-precursor-selection (SPS) MS3 scan was collected using 10 notches.
SPS-MS3 precursors were fragmented by HCD and analyzed using the Orbitrap
(NCE= 65%, AGC= 100,000, maximum injection time= 500 ms, and resolution
= 50K).
Patient-derived xenografts (PDX) analysis. Proteomic analysis of Breast cancer
PDX models, WHIM2, and WHIM16 has been described in detail elsewhere30.
Briefly, tumor chunks were snap frozen and cryopulverized. Roughly, 100 mg of
wet-weight was lysed in Urea lysis buffer as described above followed by digestion
using Trypsin and LysC and peptide purification using Sep-Pak cartridge (Waters).
For ubiquitylome analysis, the TMT10-plex experiment shown in Fig. 3, five
channels consisted of process replicates from WHIM2 and the other five channels
consisted of process replicates from WHIM16. An input of 500 μg peptide was used
for each experimental condition. K-ɛ-GG peptide enrichment and on-antibody
TMT labeling were completed exactly as described above for the TMT10-plex HeLa
cell experiment. The final TMT10 K-ɛ-GG-enriched sample was reconstituted 9 μL
of 3% MeCN/ 0.1% FA and analyzed on a Fusion Lumos mass spectrometer
(Thermo Fisher Scientific). The sample was analyzed by FAIMS-HCD-MS2 as
described for the lenalidomide-treated MM1S sample above. The sample was
analyzed using replicate 4 μL injections where only the FAIMS compensation
voltages (40, 60, 80 V) and (40, 50, and 70 V), were changed between injections.
For the proteome and acetylome analysis, a total of 300 μg of peptides were
labeled using 300ug of TMT reagent using the reduced TMT labeling protocol
described before31. TMT10-plex experiment consisted of five replicates each of
WHIM2 and WHIM16. TMT-labeled peptides were further quenched using 5%
hydroxylamine following by combining peptides at equal proportions. TMT label
peptides were further purified using Sep-Pak cartridge. Dried peptides were
resuspended in 5 mM ammonium formate and fractionated on a high pH reverse
phase chromatography unit (Zorbax 300 Extend-C18 column (3.5 μM, 250 mm;
Agilent) coupled to Agilent 1260 offline HPLC). A total of 72 fractions were
concatenated into a total of 24 fractions, 5% of which was dried down for proteome
analysis. For proteome analysis, 500 ng peptides per fraction was injected on a
Proxeon nLC1200-Thermo Lumos instrument setup running on a 110 min method
at 200 nl/min flow rate. Details of the LC and MS parameters can be found in
ref. 30. In brief, the 110-min LC-MS/MS method consisted of a 10-min column-
equilibration procedure; a 20 min sample-loading procedure; and the following
gradient profile: (min:%B) 0:2; 1:6; 85:30; 94:60; 95;90; 100:90; 101:50; 110:50 and
the last two steps were at 500 nL/min flow rate. The MS parameters are as follows:
MS1—resolution: 60,000, AGC target: 4E5, mass range: 350–1800 m/z, injection
time: 50 ms. MS2—resolution: 50,000, AGC target: 6E4, injection time: 110 ms,
isolation window: 0.7 m/z. Data-dependent mode cycle time was set to 2 s.
The residual 95% from each of 24 fractions were further concatenated. Every
fourth fraction was pooled together yielding a total of four fractions. Dried down
fractions were dissolved in 1.4 mL of 1× IAP buffer and were subjected to acetyl-
peptide enrichment using acetyl-lysine enrichment kit from Cell Signaling
Technologies. A single vial was used for the entire plex which is a total of 10 μL
beads per fraction. Peptide-antibody incubation was performed at 4 °C for 2 h,
followed by four washes using ice cold PBS. Peptides were eluted using 0.15% TFA
and purified using C18 StageTips. Acetylated peptides were analyzed using a
Proxeon nLC1200-Thermo Lumos instrument setup running on a 260 min
gradient at 200 nL/min flow rate. For acetylome and proteome analysis, the same
LC and column setup was used as the proteome, but the gradient was extended to
260 min with the following gradient profile: (min:%B) 0:2; 1:6; 235:30; 244:60;
245;90; 250:90; 251:50; 260:50 and the last two steps were at 500 nL/min flow rate.
The MS parameters were identical to MS parameters used for proteome analysis
except for MS1 and MS2 injection times of 50 and 125 ms, respectively.
Data analysis. All data were analyzed using Spectrum Mill software package v 6.1
prerelease (Agilent Technologies). For HCD-MS2, FAIMS-HCD-MS2, and SPS-
MS3 data, similar MS/MS spectra acquired on the same precursor m/z ±1.4 within
±45 s were merged. For lenalidomide-treated MM1S data, MS/MS spectra acquired
on the same precursor m/z ±1.4 within ±45 s were merged based on precursor
selection purity and spectral similarity. For SPS-MS3 data, CID-MS2 and HCD-
MS3 scans were merged from the same precursor. MS/MS spectra were excluded
from searching if they were not within the precursor MH+ range of 750–6000 Da,
or if they failed the quality filter by not having a sequence tag length >0. MS/MS
spectra were searched against a UniProt database containing 59,079 human pro-
teins. The databases were downloaded from the UniProt website and redundant
sequences were removed; and a set of common laboratory contaminant proteins
(150 sequences) was appended. All spectra were allowed ±20 ppm mass tolerance
for precursor and product ions, 30% minimum matched peak intensity, and
“trypsin allow P” enzyme specificity with up to four missed cleavages. The
instrument setting was ESI Q Exactive HCD for MS2 spectra and ESI Orbitrap for
SPS-MS3 spectra. Fragmentation mode was all for MS2 spectra, and CID for SPS-
MS3 spectra. The fixed modifications were carbamidomethylation at cysteine for all
data, and TMT10 partial-mix (N-term, K) for ubiquitylation data, and TMT10 full
Lys only-mix (N-term, K) for acetylation and proteome data. For ubiquitylation
data, allowed variable modifications were Ubiquitin Residual GG from Tryp Cut on
K, oxidized methionine, and acetylation of protein N termini with a precursor
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MH+ shift range of −134 to 375 Da. A target–decoy FDR of 1.2% was used for
ubiquitin site data. For acetylated peptide data, allowed variable modifications were
N-terminal acetylation, acetylated lysine, oxidized methionine, N-terminal pyr-
oglutamic acid, and deamidated asparagine. The precursor mass shift used
was −400 to 70 Da. For proteome searches, the above variable modifications were
used except for acetylated lysine and precursor mass shift used used was −18 to 64.
PDX proteome, acetylome, and ubiquitylome data were analyzed using RefSeq
database containing 37,592 human and 27,289 mouse entries and complemented
with common contaminants (RefSeq.20160914_Human_Mouse_ucsc_hg19_
mm10_customProDBnr_mito_150contams). Spectrum Mill sub-group specific
protein grouping feature was used to dissect human and mouse proteins. Details
have been described previously40. The relative abundance of a protein or peptide
was reported as determined using median of TMT reporter intensity from all PSMs
corresponding to the protein or peptides. TMT ratio was obtained using multi-
median approach described before30 where TMT intensity for a corresponding
channel was divided by median intensity across all channels. log2 TMT ratios were
further normalized by median centering.
For data shown in Supplementary Fig. 4e, mass spectra were also analyzed with
MaxQuant software version 1.6.0.16 using a human UniProt database to determine
the charge state distribution for the total MS1 precursor intensity for each
experiment. MS/MS searches were analyzed using oxidation of methionine, protein
N-terminal acetylation, and di-glycine remnant on lysine as variable modifications
and carbamidomethylation as a fixed modification. Trypsin/P was selected as the
digestion enzyme with a maximum of two missed cleavages per peptide. The
peptide mass tolerance was set to 20 ppm for the first search and 4.5 ppm for the
main search. The FTMS MS/MS mass tolerance was set to 20 ppm. PSM and
protein FDRs were 1% for identification. The allPeptides table was used to
determine the charge state distribution of the total MS1 precursor intensity in all
the experiments.
For ubiquitylome data generated from lenalidomide-treated MM1S cells (data
shown in Fig. 2 and Supplementary Fig. 5), TMT ratios were obtained using multi-
median approach where TMT intensity for a corresponding channel was divided by
median intensity across all channels. Log2 TMT ratios were further normalized by
median centering. We used an in-house application, Protigy (https://github.com/
broadinstitute/protigy), to perform statistical data analysis. Differential K-ɛ-GG
sites between lenalidomide-treated and non-lenalidomide-treated MM1S cells were
identified using a two-tailed two-sample moderated t-test using the limma R-
package41 implemented in Protigy. P values were adjusted for multiple hypothesis
testing using the Benjamini–Hochberg method.
For ubiquitylome data generated from Breast cancer PDX models (data shown
in Fig. 3), we identified differential K-ɛ-GG sites between WHIM2 and WHIM16
cells using a two-tailed two-sample moderated t-test as described for lenalidomide-
treated MM1S cells.
Pathway enrichment was performed using DAVID ontology enrichment tool42.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The original mass spectra and the protein sequence databases used for searches have
been deposited in the public proteomics repository MassIVE (http://massive.ucsd.edu)
and are accessible at ftp://massive.ucsd.edu/MSV000084650/. The source data underlying
Fig. 3b, Supplementary Figs. 1a, c, 3b, and 4d can be found in Supplementary Data 7a,
Supplementary Data 1, Supplementary Data 2, Supplementary Data 4, Supplementary
Data 5a, b, respectively. All other data are available from the corresponding authors on
reasonable request.
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